GO:1902992 negative regulation of amyloid precursor protein catabolic process: Proteostasis Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902992 describes any process that stops, prevents, or reduces the frequency, rate, or extent of amyloid precursor protein (APP) catabolism, thereby increasing APP abundance or altering its cleavage fate.
• APP catabolism is dominated by sequential secretase cleavage; negative regulation of this process shifts APP away from amyloidogenic processing toward non-amyloidogenic or autophagic routes.
• PPARA-mediated autophagy activation reduces Alzheimer disease-like pathology and cognitive decline in murine models, illustrating how catabolic restraint can be therapeutically engaged.
• The APP intracellular domain (AICD) regulates FOXO3a and inhibits adult hippocampal neurogenesis, linking APP catabolic intermediates to neural stem cell biology.
• Platelet APP modulates venous thromboembolism in mice, showing that APP catabolic regulation extends beyond the central nervous system.
• Plasma phospho-tau217 is now a validated diagnostic biomarker for Alzheimer disease in primary and secondary care, providing a clinical readout for APP/amyloid pathway activity.
Description
GO:1902992, negative regulation of amyloid precursor protein catabolic process, is a biological_process term in the Gene Ontology that captures any mechanism that stops, prevents, or reduces the frequency, rate, or extent of amyloid precursor protein (APP) catabolism. APP is a type I transmembrane protein whose proteolytic processing generates amyloid-beta peptides, the principal component of amyloid plaques in Alzheimer disease. Because APP catabolism sits at the intersection of proteostasis, secretase biology, and neurodegeneration, understanding its negative regulation is central to both mechanistic neuroscience and therapeutic development.
negative regulation of amyloid precursor protein catabolic process At A Glance
| GO ID | GO:1902992 |
|---|---|
| GO term | negative regulation of amyloid precursor protein catabolic process |
| Ontology | biological_process |
| Synonym | negative regulation of APP catabolism; inhibition of amyloid precursor protein degradation; downregulation of APP catabolic process |
| Major function | Restrains proteolytic and autophagic breakdown of APP, thereby modulating APP abundance and amyloid-beta generation |
| Related process | Amyloid precursor protein catabolic process (GO:0006508-related proteolysis) |
| Disease relevance | Alzheimer disease, venous thromboembolism, neuroinflammation, impaired adult hippocampal neurogenesis |
| Key regulators | PPARA, FOXO3a, Fe65, VPS4A, TSG101, METTL14 |
What Is GO:1902992?
In plain terms, GO:1902992 refers to any cellular process that slows down, blocks, or reduces the breakdown of amyloid precursor protein (APP). This includes inhibition of the secretases (alpha-, beta-, and gamma-secretase) that cleave APP, reduced delivery of APP to lysosomes or autophagosomes, and stabilization of APP or its fragments. The term is a negative regulatory node: it does not describe APP catabolism itself, but the processes that restrain it.
Why Is negative regulation of amyloid precursor protein catabolic process Important in Cell Biology?
Negative regulation of APP catabolism is important because it directly controls the amount of APP available for amyloidogenic cleavage and the production of amyloid-beta, the peptide that aggregates in Alzheimer disease. When this regulatory node is perturbed, APP can accumulate or be rerouted through alternative cleavage pathways, altering neuronal function, neurogenesis, and inflammatory signaling. Because APP is also expressed in platelets and other peripheral tissues, its catabolic regulation has implications for thrombosis and systemic disease. Moreover, viral proteins such as HIV-1 Gag compete for the same ESCRT machinery (VPS4A, TSG101) that governs APP trafficking and catabolism, linking this GO term to host-pathogen interactions.
• Controls amyloid-beta production by limiting APP access to beta- and gamma-secretases.
• Modulates adult hippocampal neurogenesis through AICD-dependent FOXO3a regulation.
• Influences Alzheimer disease-like pathology and cognitive decline in murine models.
• Affects platelet biology and venous thromboembolism risk in mice.
• Intersects with HIV-1 Gag competition for VPS4A and TSG101, linking APP catabolism to viral budding.
• Provides a mechanistic target for PPARA-mediated autophagy activation as a therapeutic strategy.
• Connects to DNA repair pathways via Fe65 nuclear localization.
• Serves as a biomarker-relevant node, with plasma phospho-tau217 reflecting downstream amyloid pathway activity.
• Relevant to astrogliosis and neuroinflammation through METTL14/DUSP1/MAPK signaling.
• Offers a tractable entry point for CRISPR-based functional genomics of APP proteostasis.
What Happens During negative regulation of amyloid precursor protein catabolic process?
Secretase inhibition and cleavage fate switching
In simple terms: The enzymes that cut APP are slowed down, so less APP is broken into amyloid-beta.
APP catabolism proceeds through alpha-, beta-, and gamma-secretase cleavage. Negative regulation of this process can occur when secretase activity is reduced or when APP is diverted away from amyloidogenic cleavage. Alpha-secretase dependent processing generates soluble APP-alpha and precludes amyloid-beta formation, and Fe65 nuclear localization downstream of alpha-secretase links this cleavage to DNA repair. PPARA-mediated autophagy activation reduces Alzheimer disease-like pathology, indicating that shifting APP catabolism toward autophagic routes can be protective.
Autophagic and lysosomal restraint
In simple terms: The cell's recycling system is tuned down, so APP is not delivered to lysosomes for destruction.
Autophagy is a major route for APP catabolism. Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model, demonstrating that autophagic flux is a lever on APP catabolism. Negative regulation of APP catabolic process can therefore involve reduced autophagosome formation, impaired autophagosome-lysosome fusion, or decreased lysosomal enzyme activity, all of which stabilize APP and its fragments.
ESCRT and trafficking competition
In simple terms: Proteins that sort APP for degradation are occupied by other cargo, so APP stays around longer.
The ESCRT machinery, including VPS4A and TSG101, governs APP trafficking and catabolism. HIV-1 Gag competes with APP for VPS4A and TSG101, and this negative interplay centers on competition for these factors, effectively reducing APP catabolic flux. This illustrates that negative regulation of APP catabolism can be imposed by exogenous viral proteins that hijack host sorting machinery.
Transcriptional and epigenetic control of APP catabolic genes
In simple terms: The cell changes which genes are turned on or off, altering how quickly APP is broken down.
Astrocytic METTL14 depletion enhances cognitive function by attenuating astrogliosis via the DUSP1/MAPK pathway in APP/PS1 mice, showing that epigenetic regulators shape APP-related pathology and neuroinflammation. AICD-dependent regulation of FOXO3a inhibits adult hippocampal neurogenesis, linking APP catabolic intermediates to transcriptional programs that control neural stem cell behavior. These examples show that negative regulation of APP catabolism is embedded in broader transcriptional and epigenetic networks.
Peripheral and platelet APP catabolic control
In simple terms: APP regulation is not just in the brain; blood cells also control how APP is broken down.
Platelet APP is a modulator of venous thromboembolism in mice, demonstrating that APP catabolic regulation has peripheral consequences. Because platelets store and release APP, changes in its catabolic processing can influence thrombosis and vascular biology. This broadens the physiological scope of GO:1902992 beyond neurodegeneration.
Key Genes Involved in GO:1902992 negative regulation of amyloid precursor protein catabolic process
The following genes and proteins are experimentally implicated in the regulation of APP catabolism and its negative control.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APP | Amyloid precursor protein; substrate of the catabolic process | Central to Alzheimer disease and amyloid-beta generation |
| PPARA | Nuclear receptor that activates autophagy | PPARA-mediated autophagy reduces AD-like pathology in mice |
| FOXO3a | Transcription factor regulated by AICD | AICD-dependent FOXO3a regulation inhibits adult hippocampal neurogenesis |
| Fe65 | APP-binding protein that localizes to the nucleus after alpha-secretase cleavage | Alpha-secretase dependent nuclear Fe65 promotes DNA repair |
| VPS4A | ESCRT-III ATPase involved in APP trafficking | Competes with HIV-1 Gag for APP sorting |
| TSG101 | ESCRT-I component involved in APP sorting | Competes with HIV-1 Gag for APP sorting |
| METTL14 | m6A RNA methyltransferase | Astrocytic METTL14 depletion attenuates astrogliosis in APP/PS1 mice |
| DUSP1 | MAPK phosphatase | Part of METTL14/DUSP1/MAPK axis in APP/PS1 mice |
| MAPK | Mitogen-activated protein kinase pathway | Downstream of DUSP1 in APP/PS1 neuroinflammation |
| ChAT | Choline acetyltransferase | Par-4 suppresses ChAT synthesis and NGF-inducibility |
| Par-4 | Pro-apoptotic protein | Induces cholinergic hypoactivity by suppressing ChAT |
| NGF | Nerve growth factor | Regulates ChAT activity and cholinergic phenotype |
| PSEN1 | Gamma-secretase catalytic subunit | Core secretase component in APP catabolism |
| PSEN2 | Gamma-secretase subunit | Core secretase component in APP catabolism |
| BACE1 | Beta-secretase | Rate-limiting enzyme for amyloidogenic APP cleavage |
| ADAM10 | Alpha-secretase | Non-amyloidogenic APP cleavage |
| APOE | Lipid transport protein | Modifies amyloid pathology risk |
| Tau | Microtubule-associated protein | Plasma phospho-tau217 is an AD biomarker |
How Is negative regulation of amyloid precursor protein catabolic process Regulated?
Negative regulation of APP catabolism is controlled at multiple levels. PPARA-mediated autophagy activation reduces Alzheimer disease-like pathology and cognitive decline in a murine model, indicating that nuclear receptor signaling can upregulate catabolic flux and thereby counteract amyloid accumulation. Conversely, when autophagy is restrained, APP catabolism is negatively regulated, favoring APP accumulation. The ESCRT pathway is another regulatory hub: HIV-1 Gag competes with APP for VPS4A and TSG101, effectively reducing APP catabolic processing. Epigenetic regulation via METTL14 and the DUSP1/MAPK pathway modulates astrogliosis and neuroinflammation in APP/PS1 mice, indirectly shaping the APP catabolic environment. Finally, AICD-dependent FOXO3a regulation links APP cleavage products to transcriptional control of adult hippocampal neurogenesis, providing a feedback layer on APP catabolism.
negative regulation of amyloid precursor protein catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APP | Alzheimer disease; amyloid-beta generation | APP/PS1 knock-in mouse; APP overexpression cell lines |
| PPARA | Alzheimer disease-like pathology; autophagy | PPARA agonist treatment in murine AD models |
| FOXO3a | Adult hippocampal neurogenesis | AICD-dependent FOXO3a reporter assays |
| VPS4A/TSG101 | HIV-1 Gag competition; APP trafficking | HIV-1 Gag overexpression with APP in HEK293 cells |
| METTL14 | Astrogliosis; neuroinflammation in AD | Astrocytic METTL14 conditional knockout in APP/PS1 mice |
Alzheimer disease and amyloid pathology
Alzheimer disease is defined pathologically by amyloid plaques and neurofibrillary tangles. Negative regulation of APP catabolism increases the pool of APP available for amyloidogenic cleavage, promoting amyloid-beta generation. Plasma phospho-tau217 has emerged as a fully automated diagnostic biomarker for Alzheimer disease in primary and secondary care, reflecting downstream amyloid pathway activity. PPARA-mediated autophagy activation reduces AD-like pathology and cognitive decline in murine models, supporting the therapeutic hypothesis that enhancing APP catabolism is beneficial.
Neurogenesis and cognitive function
APP catabolic intermediates such as AICD regulate FOXO3a and inhibit adult hippocampal neurogenesis, linking APP processing to cognitive function. Astrocytic METTL14 depletion enhances cognitive function by attenuating astrogliosis via the DUSP1/MAPK pathway in APP/PS1 mice, demonstrating that epigenetic and inflammatory modulation can rescue cognitive phenotypes. These findings position negative regulation of APP catabolism as a determinant of neural stem cell activity and cognitive resilience.
Thrombosis and peripheral APP biology
Platelet APP is a modulator of venous thromboembolism in mice, showing that APP catabolic regulation influences hemostasis and thrombosis. Because platelets release APP and its fragments, altered catabolic processing may change thrombotic risk. This peripheral dimension broadens the disease relevance of GO:1902992 beyond the central nervous system.
Host-pathogen interactions and viral budding
HIV-1 Gag competes with APP for VPS4A and TSG101, and this negative interplay centers on competition for these ESCRT factors. As a result, HIV-1 infection can negatively regulate APP catabolism by sequestering shared trafficking machinery. This highlights how infectious agents can impinge on APP proteostasis and potentially contribute to neurocognitive complications.
From negative regulation of amyloid precursor protein catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase APP catabolism? | CRISPR knockout of candidate gene in neuronal cell lines |
| Does a point mutation in APP alter its catabolic fate? | Point-mutation knock-in of APP variants |
| Does tagging APP reveal its trafficking and catabolism? | Tagged knock-in of APP with fluorescent or epitope tag |
| Does overexpression of PPARA enhance APP catabolism? | PPARA overexpression in APP/PS1 mice or cell lines |
| Does ESCRT competition regulate APP catabolism? | VPS4A/TSG101 knockout or overexpression with HIV-1 Gag |
| Does epigenetic modulation affect APP catabolism? | METTL14 knockout in astrocytes of APP/PS1 mice |
How to Study the negative regulation of amyloid precursor protein catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effect on APP catabolism | Testing candidate genes such as PPARA, VPS4A, TSG101 |
| Point-mutation knock-in | Effect of specific APP or secretase mutations | Dissecting cleavage site usage |
| Tagged knock-in | APP localization and trafficking | Live-cell imaging of APP |
| Overexpression | Gain-of-function effect on APP catabolism | PPARA overexpression in AD models |
| Proteomics | APP fragment and interactome quantification | Identifying Fe65 and ESCRT interactions |
| Autophagy flux assays | LC3-II turnover and p62 degradation | Measuring autophagic APP catabolism |
| Plasma phospho-tau217 assay | Downstream amyloid pathway activity | Clinical AD diagnosis |
| Immunoprecipitation | Protein-protein interactions | Detecting APP-Fe65 and APP-ESCRT complexes |
CRISPR knockout and point-mutation screens
CRISPR knockout of candidate genes such as PPARA, VPS4A, TSG101, or METTL14 can test whether loss of function alters APP catabolism. Point-mutation knock-in of APP or secretase genes can dissect cleavage site usage and catabolic fate. These approaches are foundational for assigning causal roles to genes within GO:1902992.
Proteomics and APP fragment analysis
Mass spectrometry-based proteomics can quantify APP and its cleavage fragments (sAPP-alpha, sAPP-beta, AICD, amyloid-beta) to measure catabolic flux. Immunoprecipitation of tagged APP followed by mass spectrometry identifies interacting partners such as Fe65 and ESCRT components. These methods provide direct biochemical evidence of negative regulation.
Autophagy and lysosomal flux assays
LC3-II turnover, p62 degradation, and lysosomal pH measurements assess autophagic flux, which is a major route for APP catabolism. PPARA-mediated autophagy activation reduces AD-like pathology, so these assays are directly relevant to GO:1902992. Combining flux assays with APP fragment analysis links autophagic activity to APP catabolic output.
Imaging and biomarker quantification
Live-cell imaging of fluorescently tagged APP can track its trafficking from the plasma membrane to endosomes and lysosomes. Plasma phospho-tau217 quantification using fully automated platforms provides a clinical biomarker readout of amyloid pathway activity. These imaging and biomarker approaches bridge mechanistic cell biology and human disease.
How CRISPR Can Be Used to Study GO:1902992 negative regulation of amyloid precursor protein catabolic process
Knockout
CRISPR knockout of genes such as PPARA, VPS4A, TSG101, or METTL14 can determine whether their loss alters APP catabolic flux. For example, knocking out ESCRT components may mimic the negative regulation imposed by HIV-1 Gag competition. Knockout models are essential for establishing causality within GO:1902992.
Point Mutation
Point-mutation knock-in of APP at secretase cleavage sites can shift APP toward or away from amyloidogenic processing. Similarly, point mutations in secretase genes can alter catabolic efficiency. These models allow precise dissection of how single amino acid changes affect negative regulation of APP catabolism.
Knock-in
Tagged knock-in of APP with fluorescent or epitope tags enables real-time tracking of APP trafficking and catabolism. Knock-in of disease-associated APP variants in mice or cells provides physiologically relevant models. These models are valuable for studying how genetic variants influence GO:1902992.
Overexpression
Overexpression of PPARA or other autophagy regulators can enhance APP catabolism and reduce AD-like pathology in murine models. Conversely, overexpression of HIV-1 Gag can sequester VPS4A and TSG101, negatively regulating APP catabolism. Overexpression models are useful for gain-of-function studies of GO:1902992.
How EDITGENE Supports negative regulation of amyloid precursor protein catabolic process Research
Researchers studying negative regulation of amyloid precursor protein catabolic process-related genes often need to determine whether a candidate gene is causally involved in APP proteostasis or merely correlated with it. EDITGENE provides end-to-end CRISPR services to generate knockout, point-mutation, knock-in, and overexpression cell models, enabling rigorous functional validation of genes within GO:1902992.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of amyloid precursor protein catabolic process research.
Frequently Asked Questions About negative regulation of amyloid precursor protein catabolic process
What is GO:1902992?
GO:1902992 is the Gene Ontology term for negative regulation of amyloid precursor protein catabolic process, describing any process that stops, prevents, or reduces the breakdown of APP.
What genes are involved in negative regulation of amyloid precursor protein catabolic process?
Key genes include APP, PPARA, FOXO3a, Fe65, VPS4A, TSG101, METTL14, and DUSP1, among others.
How does negative regulation of APP catabolism affect Alzheimer disease?
It increases the pool of APP available for amyloidogenic cleavage, promoting amyloid-beta generation and AD pathology.
What is the role of PPARA in APP catabolism?
PPARA-mediated autophagy activation reduces Alzheimer disease-like pathology and cognitive decline in murine models.
How does HIV-1 Gag affect APP catabolism?
HIV-1 Gag competes with APP for VPS4A and TSG101, negatively regulating APP catabolism.
What is the relationship between AICD and FOXO3a?
AICD-dependent regulation of FOXO3a inhibits adult hippocampal neurogenesis.
Can platelet APP influence thrombosis?
Yes, platelet APP is a modulator of venous thromboembolism in mice.
What role does METTL14 play in APP/PS1 mice?
Astrocytic METTL14 depletion enhances cognitive function by attenuating astrogliosis via the DUSP1/MAPK pathway.
How is plasma phospho-tau217 used in Alzheimer disease diagnosis?
Plasma phospho-tau217 is a fully automated diagnostic biomarker for Alzheimer disease in primary and secondary care.
What experimental models are used to study GO:1902992?
CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models in cell lines and APP/PS1 mice are commonly used.
Conclusion
GO:1902992, negative regulation of amyloid precursor protein catabolic process, is a critical node in APP proteostasis with direct implications for Alzheimer disease, neurogenesis, thrombosis, and host-pathogen interactions. Understanding the genes and mechanisms that restrain APP catabolism provides a foundation for therapeutic strategies aimed at promoting APP clearance and reducing amyloid-beta production. CRISPR-based models and advanced proteomic and imaging methods are essential tools for dissecting this regulatory process and translating findings into clinical benefit.
References
- 1. Luo R et al.. 2020. Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model.. Autophagy 16(1):52-69 PMID: 30898012
- 2. Palmqvist S et al.. 2025. Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform.. Nat Med 31(6):2036-2043 PMID: 40205199
- 3. Jiang M et al.. 2020. Amyloid precursor protein intracellular domain-dependent regulation of FOXO3a inhibits adult hippocampal neurogenesis.. Neurobiol Aging 95:250-263 PMID: 32866886
- 4. Guo Q et al.. 2000. Par-4 induces cholinergic hypoactivity by suppressing ChAT protein synthesis and inhibiting NGF-inducibility of ChAT activity.. Brain Res 874(2):221-32 PMID: 10960608
- 5. Canobbio I et al.. 2017. Platelet amyloid precursor protein is a modulator of venous thromboembolism in mice.. Blood 130(4):527-536 PMID: 28611024
- 6. Gu F et al.. 2025. Negative interplay between HIV-1 Gag and amyloid precursor protein centers around competition for VPS4A and TSG101.. Proc Natl Acad Sci U S A 122(34):e2503988122 PMID: 40838881
- 7. Teng Y et al.. 2026. Astrocytic Mettl14 depletion enhances cognitive function by attenuating astrogliosis via the DUSP1/MAPK pathway in APP/PS1 mice: targeting neuroinflammation in Alzheimer's disease.. Mol Psychiatry 31(1):318-331 PMID: 40914755
- 8. Revol RS et al.. 2023. Alpha-secretase dependent nuclear localization of the amyloid-β precursor protein-binding protein Fe65 promotes DNA repair.. Mol Cell Neurosci 127:103903 PMID: 37918552
